Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3396 - Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Norbert Marschner


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


N. Marschner1, U. von Verschuer2, R. Schnell3, M. Zahn4, J. Eggert5, A. Binninger6, L. Spring6, M. Jänicke6

Author affiliations

  • 1 Oncology And Hematology, Praxis für interdisziplinäre Onkologie & Hämatologie, 79110 - Freiburg/DE
  • 2 Oncology And Hematology, MVZ für Hämatologie und Onkologie Essen gGmbH, 45136 - Essen/DE
  • 3 Oncology And Hematology, Praxis Internistischer Onkologie und Hämatologie (PIOH), 50226 - Frechen/DE
  • 4 Oncology And Hematology, Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz, Goslar/DE
  • 5 Oncology And Hematology, Gemeinschaftspraxis für Innere Medizin, Moers/DE
  • 6 Clinical Epidemiology And Health Economics, iOMEDICO AG, 79108 - Freiburg/DE


Abstract 3396


Lung cancer is the leading cause of cancer-related mortality and the majority of patients (pts) are diagnosed with advanced or metastatic disease. Despite advances in targeted therapies for selected patient subgroups, the majority of pts (∼80%) are treated with platinum-based doublet chemotherapies (CT). The choice between the platinum agents cisplatin (CIS) or carboplatin (CAR) has been subject of a long debate. Here we present data on the treatment of advanced non-small cell lung cancer (aNSCLC) in routine practice. Such real-world data are of central importance to improve the standard of care.


107 sites in Germany recruited 1,239 pts with aNSCLC at start of 1st-line therapy into the prospective clinical cohort study TLK (Tumour Registry Lung Cancer) between Feb 2010 and Dec 2013. Details on systemic treatment and outcome were collected until Jan 2016. A longitudinal health-related quality of life (HRQOL) analysis using the questionnaires EORTC QLQ-C30 and –LC13 was conducted every 2 months (mts) for a period of up to 10 months.


46% of the pts received CAR- and 35% CIS-based doublet CT in 1st-line treatment. Pts receiving CIS- were younger than pts receiving CAR-combinations (median age at start of treatment 62 vs. 69 years), more often had a good performance status (33% vs. 17% ECOG =0) and less comorbidities (34% vs. 56% Charlson Comorbidity Index ≥1). The main combination partner was pemetrexed for CIS (33%) and paclitaxel for CAR (24%). Median overall survival was 11.9 mts (95% CI 10.2-13.8) for CIS- and 12.2 mts (95% CI 10.0-13.3) for CAR-combinations. The median time to deterioration of the global health status was 6.8 mts for CIS- and 6.4 mts for CAR-combinations. Considerable deteriorations in the symptoms nausea, fatigue, dyspnoea and pain were reported after 4-6 mts, with no difference between CIS and CAR.


Numerous meta analyses have been dedicated to finding the optimal platinum agent for the 1st-line treatment of aNSCLC. With our data from the prospective, population-based cohort study TLK, we complement the results from clinical trials. We show that there is no considerable difference in outcome or HRQOL between CIS- and CAR-combinations in the treatment of aNSCLC.

Clinical trial identification


Legal entity responsible for the study



Roche Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Onkovis GmbH, TEVA Deutschland GmbH


N. Marschner: Roche Pharma AG: Travel Grant + Advisory Board Fee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.